Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of the skin irritating properties of HP-1040 in healthy middle-aged adults
jRCTs031190145Completed
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised trial of rivastigmine (2 arms), sponsored by Hisamitsu Pharmaceutical Co., Inc. Primary endpoint: Skin irritation score. Started Jan 2020; status: completed.
02
Drugs
rivastigmine
Beyond the preview
Go deeper on jRCTs031190145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190145.